Search

Search Constraints

You searched for: Author/Creator Spicka, Ivan

Search Results

1. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up. (7th July 2015)

2. Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. Issue 12 (2nd December 2021)

3. Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse. Issue 11 (29th January 2018)

4. Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. (6th August 2019)

5. Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Issue 6 (3rd May 2021)

6. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Issue 1 (January 2021)

7. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth. (5th July 2017)

8. Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA. (November 2022)

9. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Issue 13 (18th May 2016)

10. Health‐related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. (8th February 2021)